http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6500827-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 |
| filingDate | 2001-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7f09d818cf6055fce51c839e3956015 |
| publicationDate | 2002-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6500827-B2 |
| titleOfInvention | Drug combinations |
| abstract | This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003078262-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004034106-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010069389-A1 |
| priorityDate | 1998-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 109.